Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette–Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure.
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)☆
Annals of Oncology | | M. Roupret, A. Bertaut, G. Pignot, Y. Neuzillet, N. Houede, R. Mathieu, L. Corbel, D. Besson, T. Seisen, L. Jaffrelot, C. Lebacle, S. Champiat, S. Lebdai, M.-O. Timsit, C. Thibault, L. Goeman, Á. Juárez Soto, C. La, C. Léger, Y. Loriot
Topics: bladder-cancer, immunotherapy, clinical-trials